Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.25
ESRX's Cash-to-Debt is ranked lower than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. ESRX: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
ESRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: No Debt
Current: 0.25
0.03
No Debt
Equity-to-Asset 0.37
ESRX's Equity-to-Asset is ranked lower than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. ESRX: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
ESRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.34 Max: 0.72
Current: 0.37
0.11
0.72
Debt-to-Equity 0.73
ESRX's Debt-to-Equity is ranked lower than
84% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. ESRX: 0.73 )
Ranked among companies with meaningful Debt-to-Equity only.
ESRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.89 Max: 4.16
Current: 0.73
0.05
4.16
Debt-to-EBITDA 2.04
ESRX's Debt-to-EBITDA is ranked lower than
56% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. ESRX: 2.04 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ESRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08  Med: 2.3 Max: 3.39
Current: 2.04
1.08
3.39
Interest Coverage 8.56
ESRX's Interest Coverage is ranked lower than
52% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. ESRX: 8.56 )
Ranked among companies with meaningful Interest Coverage only.
ESRX' s Interest Coverage Range Over the Past 10 Years
Min: 4.51  Med: 7.71 Max: 16.5
Current: 8.56
4.51
16.5
Piotroski F-Score: 8
Altman Z-Score: 3.43
Beneish M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.27
ESRX's Operating Margin % is ranked higher than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. ESRX: 5.27 )
Ranked among companies with meaningful Operating Margin % only.
ESRX' s Operating Margin % Range Over the Past 10 Years
Min: 2.98  Med: 4.81 Max: 6.06
Current: 5.27
2.98
6.06
Net Margin % 4.83
ESRX's Net Margin % is ranked higher than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. ESRX: 4.83 )
Ranked among companies with meaningful Net Margin % only.
ESRX' s Net Margin % Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 4.83
Current: 4.83
1.4
4.83
ROE % 26.51
ESRX's ROE % is ranked higher than
85% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. ESRX: 26.51 )
Ranked among companies with meaningful ROE % only.
ESRX' s ROE % Range Over the Past 10 Years
Min: 8.16  Med: 23.28 Max: 87.47
Current: 26.51
8.16
87.47
ROA % 9.11
ESRX's ROA % is ranked higher than
75% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. ESRX: 9.11 )
Ranked among companies with meaningful ROA % only.
ESRX' s ROA % Range Over the Past 10 Years
Min: 3.3  Med: 7.51 Max: 14.42
Current: 9.11
3.3
14.42
ROC (Joel Greenblatt) % 404.83
ESRX's ROC (Joel Greenblatt) % is ranked higher than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. ESRX: 404.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ESRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 220.38  Med: 402.33 Max: 589.99
Current: 404.83
220.38
589.99
3-Year Revenue Growth Rate 8.90
ESRX's 3-Year Revenue Growth Rate is ranked higher than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. ESRX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ESRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 23.8 Max: 86.2
Current: 8.9
5.3
86.2
3-Year EBITDA Growth Rate 17.50
ESRX's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. ESRX: 17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ESRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 15  Med: 24.8 Max: 66
Current: 17.5
15
66
3-Year EPS without NRI Growth Rate 43.10
ESRX's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. ESRX: 43.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ESRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 28.1 Max: 74.6
Current: 43.1
0
74.6
GuruFocus has detected 2 Warning Signs with Express Scripts Holding Co ESRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ESRX's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

ESRX Guru Trades in Q1 2018

George Soros 30,500 sh (New)
Jeremy Grantham 208,300 sh (New)
Jim Simons 1,398,039 sh (New)
Larry Robbins 4,641,986 sh (New)
Ken Fisher 401,090 sh (+32.67%)
Ronald Muhlenkamp 129,559 sh (+114.36%)
Leucadia National 24,251 sh (+219.22%)
Dodge & Cox 34,977,619 sh (+0.60%)
Joel Greenblatt 768,923 sh (+8.16%)
Paul Tudor Jones 51,770 sh (+29.55%)
Pioneer Investments 638,424 sh (+1.79%)
David Dreman 15,063 sh (unchged)
Yacktman Asset Management 15,200 sh (unchged)
Mario Gabelli 11,200 sh (unchged)
Glenn Greenberg Sold Out
Seth Klarman Sold Out
First Eagle Investment Sold Out
First Pacific Advisors Sold Out
Diamond Hill Capital Sold Out
Ray Dalio Sold Out
David Rolfe Sold Out
Jeff Ubben Sold Out
Charles Brandes 1,424,677 sh (-17.09%)
Chris Davis 385,436 sh (-90.16%)
Richard Pzena 3,106,946 sh (-13.76%)
Jeff Auxier 84,834 sh (-0.05%)
Barrow, Hanley, Mewhinney & Strauss 14,404,431 sh (-15.74%)
» More
Q2 2018

ESRX Guru Trades in Q2 2018

Glenn Greenberg 1,249,627 sh (New)
John Hussman 35,800 sh (New)
David Abrams 2,653,101 sh (New)
Ken Fisher 416,456 sh (+3.83%)
George Soros 85,200 sh (+179.34%)
Leucadia National 46,824 sh (+93.08%)
Dodge & Cox 41,463,656 sh (+18.54%)
Chris Davis 387,178 sh (+0.45%)
Jeremy Grantham 1,320,908 sh (+534.14%)
Paul Tudor Jones 80,985 sh (+56.43%)
Pioneer Investments 807,517 sh (+26.49%)
Larry Robbins 6,979,569 sh (+50.36%)
Jeremy Grantham 217,000 sh (unchged)
Yacktman Asset Management Sold Out
Jim Simons Sold Out
Ronald Muhlenkamp 129,511 sh (-0.04%)
Joel Greenblatt 429,168 sh (-44.19%)
Charles Brandes 1,394,914 sh (-2.09%)
Richard Pzena 3,103,548 sh (-0.11%)
Barrow, Hanley, Mewhinney & Strauss 13,799,574 sh (-4.20%)
Mario Gabelli 8,200 sh (-26.79%)
Jeff Auxier 84,740 sh (-0.11%)
» More
Q3 2018

ESRX Guru Trades in Q3 2018

John Paulson 60,000 sh (New)
Murray Stahl 2,284 sh (New)
Mario Gabelli 35,900 sh (+337.80%)
David Abrams 3,192,304 sh (+20.32%)
Chris Davis 387,902 sh (+0.19%)
George Soros 271,711 sh (+218.91%)
Larry Robbins 8,603,438 sh (+23.27%)
Glenn Greenberg Sold Out
Ken Fisher 12,641 sh (-96.96%)
John Hussman 800 sh (-97.77%)
Charles Brandes 1,229,788 sh (-11.84%)
Richard Pzena 3,054,162 sh (-1.59%)
Barrow, Hanley, Mewhinney & Strauss 13,511,900 sh (-2.08%)
Ronald Muhlenkamp 128,695 sh (-0.63%)
Jeremy Grantham 308,600 sh (-76.64%)
Pioneer Investments 513,622 sh (-36.39%)
Leucadia National 43,704 sh (-6.66%)
Joel Greenblatt 346,758 sh (-19.20%)
Paul Tudor Jones 47,500 sh (-41.35%)
Jeff Auxier 84,559 sh (-0.21%)
Dodge & Cox 39,936,856 sh (-3.68%)
» More
Q4 2018

ESRX Guru Trades in Q4 2018

Ken Fisher Sold Out
Mario Gabelli Sold Out
John Hussman Sold Out
Richard Pzena Sold Out
Charles Brandes Sold Out
Chris Davis Sold Out
Jeremy Grantham Sold Out
Barrow, Hanley, Mewhinney & Strauss Sold Out
Jeff Auxier Sold Out
David Abrams Sold Out
Leucadia National Sold Out
Murray Stahl Sold Out
Dodge & Cox Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Joel Greenblatt Sold Out
John Paulson Sold Out
George Soros Sold Out
Larry Robbins Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 446110    SIC: 5912
Compare:NYSE:CI, NYSE:HUM, NYSE:AET, NYSE:ANTM, NYSE:CNC, NYSE:CVS, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:ESRX.Austria, ESRX34.Brazil, 4XS.Germany, ESRX.Mexico, ESRX.Switzerland, 0R0W.UK,
Headquarter Location:USA
Express Scripts Holding Co is a pharmacy benefit manager in the United States. It offers healthcare management and administration services such as managed care organizations, health insurers, workers' compensation plans and government health programs.

Express Scripts is the largest pharmacy benefit manager in the United States. Through its mail-order pharmacy and network of retail pharmacies, Express Scripts processes approximately 1.3 billion adjusted prescriptions annually for its payer clients.

Guru Investment Theses on Express Scripts Holding Co

Jeff Auxier Comments on Express Scripts Holding - Nov 08, 2018

Express Scripts Holding Co. (NASDAQ:ESRX) 23.05% Cigna is acquiring pharmacy benefit manager Express Scripts for an estimated $67B or over $95 a share. The deal includes $48.75 in cash and 0.2434 shares of Cigna for each share of Express Scripts and is expected to close by the end of the year. We originally invested in ESRX at $7.63 a share after a face-to-face meeting with management late on a Friday.



From Jeff Auxier (Trades, Portfolio)'s third-quarter 2018 shareholder commentary.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Express Scripts - Feb 06, 2018

Express Scripts (NASDAQ:ESRX) recently acquired eviCore Healthcare, an industry leader in evidence-based medical benefit management services. EviCore helps manage medical benefits for 100 million people, and Express Scripts expects the acquisition to be accretive to adjusted diluted earnings per share in 2018, which they now estimate in the range of $7.67 to $7.87. At a P/E of 12 times 2018 the stock seems very cheap.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Express Scripts Holding Co

Richard Pzena Exits Express Scripts, Reduces Dover Guru's largest sales of the 4th quarter
Richard Pzena (Trades, Portfolio), the founder and co-chief investment officer of Pzena Investment Management, sold shares of the following stocks during the fourth quarter. Read more...
5 Health Care Stocks Gurus Are Buying Gilead on the list
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors. Read more...
Celanese Set to Join S&P 500
Petco and Express Scripts Team Up to Revolutionize Home Delivery of Pet Medicines
Express Scripts Introduces Novel Formulary Built for Evolution of Drug Pricing
Jeff Auxier Comments on Express Scripts Holding Guru stock highlight
Express Scripts Holding Co. (NASDAQ:ESRX) 23.05% Cigna is acquiring pharmacy benefit manager Express Scripts for an estimated $67B or over $95 a share. The deal includes $48.75 in cash and 0.2434 shares of Cigna for each share of Express Scripts and is expected to close by the end of the year. We originally invested in ESRX at $7.63 a share after a face-to-face meeting with management late on a Friday.
Read more...
Express Scripts' myMatrixx Launches myDataSense Analytics Tool
Express Scripts' Innovative Advanced Opioid Management Solution Shifts First-Time Opioid Users to Safer, Short-Term Prescriptions
National Drug Purchasing Coalition - member companies include PepsiCo, Inc. and ExxonMobil - and Express Scripts Team Up to Create New Pharmacy Benefit Design for Greater Performance Accountability, Transparency, and Alignment
Express Scripts Offers New Value-Based Program for Migraine

Ratios

vs
industry
vs
history
PE Ratio 10.79
ESRX's PE Ratio is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 10.79 )
Ranked among companies with meaningful PE Ratio only.
ESRX' s PE Ratio Range Over the Past 10 Years
Min: 8.31  Med: 24.8 Max: 36.23
Current: 10.79
8.31
36.23
Forward PE Ratio 9.73
ESRX's Forward PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. ESRX: 9.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.79
ESRX's PE Ratio without NRI is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 10.79 )
Ranked among companies with meaningful PE Ratio without NRI only.
ESRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.31  Med: 24.34 Max: 35.5
Current: 10.79
8.31
35.5
Price-to-Owner-Earnings 13.54
ESRX's Price-to-Owner-Earnings is ranked higher than
94% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. ESRX: 13.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ESRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 13.32 Max: 27.84
Current: 13.54
5.68
27.84
PB Ratio 2.53
ESRX's PB Ratio is ranked higher than
73% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. ESRX: 2.53 )
Ranked among companies with meaningful PB Ratio only.
ESRX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 3.03 Max: 29.46
Current: 2.53
1.85
29.46
PS Ratio 0.52
ESRX's PS Ratio is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. ESRX: 0.52 )
Ranked among companies with meaningful PS Ratio only.
ESRX' s PS Ratio Range Over the Past 10 Years
Min: 0.34  Med: 0.56 Max: 1.04
Current: 0.52
0.34
1.04
Price-to-Free-Cash-Flow 13.01
ESRX's Price-to-Free-Cash-Flow is ranked higher than
89% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. ESRX: 13.01 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ESRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.7  Med: 12.9 Max: 24.11
Current: 13.01
5.7
24.11
Price-to-Operating-Cash-Flow 12.02
ESRX's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. ESRX: 12.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ESRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.46  Med: 12.02 Max: 21.95
Current: 12.02
5.46
21.95
EV-to-EBIT 11.75
ESRX's EV-to-EBIT is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. ESRX: 11.75 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.2  Med: 14.7 Max: 30.2
Current: 11.75
8.2
30.2
EV-to-EBITDA 8.62
ESRX's EV-to-EBITDA is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. ESRX: 8.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.3 Max: 22.4
Current: 8.62
6.1
22.4
EV-to-Revenue 0.63
ESRX's EV-to-Revenue is ranked higher than
67% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. ESRX: 0.63 )
Ranked among companies with meaningful EV-to-Revenue only.
ESRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 1.2
Current: 0.63
0.4
1.2
PEG Ratio 0.70
ESRX's PEG Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.70 )
Ranked among companies with meaningful PEG Ratio only.
ESRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.97 Max: 1.69
Current: 0.7
0.43
1.69
Shiller PE Ratio 25.04
ESRX's Shiller PE Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. ESRX: 25.04 )
Ranked among companies with meaningful Shiller PE Ratio only.
ESRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.5  Med: 42.4 Max: 73.72
Current: 25.04
19.5
73.72
Current Ratio 0.77
ESRX's Current Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.77 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.9 Max: 5.57
Current: 0.77
0.55
5.57
Quick Ratio 0.65
ESRX's Quick Ratio is ranked lower than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.8 Max: 4.78
Current: 0.65
0.47
4.78
Days Inventory 8.43
ESRX's Days Inventory is ranked higher than
55% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. ESRX: 8.43 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s Days Inventory Range Over the Past 10 Years
Min: 3.02  Med: 5.49 Max: 8.43
Current: 8.43
3.02
8.43
Days Sales Outstanding 14.66
ESRX's Days Sales Outstanding is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. ESRX: 14.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.11  Med: 15.16 Max: 24.11
Current: 14.66
14.11
24.11
Days Payable 17.43
ESRX's Days Payable is ranked lower than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. ESRX: 17.43 )
Ranked among companies with meaningful Days Payable only.
ESRX' s Days Payable Range Over the Past 10 Years
Min: 5.7  Med: 11.91 Max: 17.43
Current: 17.43
5.7
17.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 8.10
ESRX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. ESRX: 8.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.4  Med: -0.5 Max: 8.1
Current: 8.1
-14.4
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.67
ESRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. ESRX: 0.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ESRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.36 Max: 62.6
Current: 0.67
0.49
62.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.46
ESRX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. ESRX: 0.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ESRX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.37  Med: 1.79 Max: 2.99
Current: 0.46
0.37
2.99
Price-to-Median-PS-Value 0.92
ESRX's Price-to-Median-PS-Value is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. ESRX: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ESRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.07 Max: 6
Current: 0.92
0.56
6
Price-to-Peter-Lynch-Fair-Value 0.72
ESRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
91% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. ESRX: 0.72 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ESRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.09 Max: 2.44
Current: 0.72
0.38
2.44
Earnings Yield (Greenblatt) % 8.51
ESRX's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. ESRX: 8.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ESRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 6.8 Max: 12.2
Current: 8.51
3.3
12.2
Forward Rate of Return (Yacktman) % 22.78
ESRX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. ESRX: 22.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ESRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 22.1  Med: 24.6 Max: 27.6
Current: 22.78
22.1
27.6

More Statistics

Revenue (TTM) (Mil) $101,353.20
EPS (TTM) $ 8.56
Volatility22.47%
52-Week Range $66.93 - 101.73
Shares Outstanding (Mil)563.86

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 101,614 104,436
EBIT (Mil $) 6,682 6,898
EBITDA (Mil $) 7,861 7,955
EPS ($) 7.64 8.21
EPS without NRI ($) 7.64 8.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.03%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}